Eli Lilly And Co (LLY) is Holistic Financial Partners’ 2nd Largest Position

Holistic Financial Partners cut its stake in Eli Lilly And Co (NYSE:LLY) by 21.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,986 shares of the company’s stock after selling 21,935 shares during the period. Eli Lilly And Co comprises about 8.1% of Holistic Financial Partners’ holdings, making the stock its 2nd largest holding. Holistic Financial Partners’ holdings in Eli Lilly And Co were worth $8,691,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in LLY. Gyroscope Capital Management Group LLC lifted its holdings in Eli Lilly And Co by 0.5% during the 3rd quarter. Gyroscope Capital Management Group LLC now owns 89,849 shares of the company’s stock worth $10,334,000 after buying an additional 469 shares during the last quarter. Bbva Compass Bancshares Inc. lifted its holdings in Eli Lilly And Co by 5.3% during the 3rd quarter. Bbva Compass Bancshares Inc. now owns 9,349 shares of the company’s stock worth $1,003,000 after buying an additional 474 shares during the last quarter. Pure Financial Advisors Inc. lifted its holdings in Eli Lilly And Co by 18.3% during the 3rd quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock worth $340,000 after buying an additional 490 shares during the last quarter. Balasa Dinverno & Foltz LLC lifted its holdings in Eli Lilly And Co by 15.9% during the 3rd quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock worth $389,000 after buying an additional 499 shares during the last quarter. Finally, Legacy Private Trust Co. lifted its holdings in Eli Lilly And Co by 5.2% during the 3rd quarter. Legacy Private Trust Co. now owns 10,365 shares of the company’s stock worth $1,112,000 after buying an additional 508 shares during the last quarter. Hedge funds and other institutional investors own 76.17% of the company’s stock.

LLY has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Eli Lilly And Co in a report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 price target for the company. Goldman Sachs Group set a $100.00 price target on Eli Lilly And Co and gave the stock a “neutral” rating in a report on Wednesday, July 25th. Credit Suisse Group lifted their price target on Eli Lilly And Co from $84.00 to $86.00 and gave the stock an “underperform” rating in a report on Wednesday, July 25th. BMO Capital Markets upgraded Eli Lilly And Co from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $107.00 to $130.00 in a research report on Thursday, October 4th. Finally, Berenberg Bank cut Eli Lilly And Co from a “buy” rating to a “hold” rating and set a $99.00 target price on the stock. in a research report on Wednesday, July 25th. They noted that the move was a valuation call. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $111.19.

In related news, major shareholder Lilly Endowment Inc sold 3,587 shares of the business’s stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $103.06, for a total value of $369,676.22. Following the transaction, the insider now owns 120,707,597 shares in the company, valued at approximately $12,440,124,946.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Eli & Co Lilly sold 4,531 shares of the business’s stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $14.33, for a total value of $64,929.23. Following the completion of the transaction, the insider now owns 3,934,137 shares in the company, valued at approximately $56,376,183.21. The disclosure for this sale can be found here. Insiders sold a total of 1,185,271 shares of company stock worth $123,843,752 in the last 90 days. 0.11% of the stock is currently owned by insiders.

LLY opened at $109.72 on Thursday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The stock has a market cap of $113.74 billion, a PE ratio of 25.64, a PEG ratio of 1.69 and a beta of 0.29.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 44.13% and a net margin of 1.85%. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The business’s revenue was up 7.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Eli Lilly And Co will post 5.58 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be given a $0.5625 dividend. This represents a $2.25 annualized dividend and a yield of 2.05%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

TRADEMARK VIOLATION WARNING: “Eli Lilly And Co (LLY) is Holistic Financial Partners’ 2nd Largest Position” was first published by WKRB News and is the property of of WKRB News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.wkrb13.com/2018/11/08/eli-lilly-and-co-lly-is-holistic-financial-partners-2nd-largest-position.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Understanding Relative Strength Index

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply